Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

REINACH, Switzerland, February 25 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the year ending 31 December 2008.

    2008 Key Events

      - Setback in regulatory process for intravenous iclaprim in US
      - Restructuring and focus on iclaprim
      - Top-line results of "intravenous-to-oral" Phase II trial with oral
        iclaprim
      - Leadership change
      - Share placing

    Cash and financial investments of CHF 38.7 million at 31 December 2008

    Post-Year-End Event

      - January 2009: FDA issues Complete Response Letter

    2009 Priorities

      - Finalise restructuring
      - Design a roadmap for approval of intravenous iclaprim
      - Consider and develop strategic options

Dr Jurgen Raths, President and CEO, commented: "The negative FDA response of last January was a serious blow to our company and all of its stakeholders. The steps we have announced and executed, though painful, were unavoidable. We are currently pursuing several strategies to maximise shareholder value. This includes partnering, mergers and acquisitions as well as the disposal of certain assets as we do not have the money nor the time required to further develop iclaprim on our own."

CFO Harry Welten, MBA, added: "Our cash balance at year-end 2008 was in line with our earlier guidance. We maintain our forecast that cash and financial investments will amount to approximately CHF 17 million at year-end 2009."

    Financial review for twelve months to 31 December 2008

    Key financial indicators


    CHF million                        2008    2007

    Research and development expenses (43.8)  (45.0)
    Management and general expenses   (13.4)  (15.4)
    Restructuring expenses            (12.6)      -
    Total operating expenses          (69.9)  (60.4)
    Net result                        (66.5)  (59.1)

   
'/>"/>
SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... MA (PRWEB) May 26, 2015 Just ... addresses a long-standing unmet biomedical need does not guarantee ... a problem that has seen many prior failures is ... gaining acceptance and use is an irony that is ... a small, new start-up company, Asymmetrex has ...
(Date:5/25/2015)... BOSTON , May 26, 2015  PureTech, a ... toughest health challenges in disruptive ways, announced today that ... Foundation and former CEO of Pearson, has been appointed ... Senior Independent Director and that current Board member ... appointed Board Chairman. Dr. Ben Shapiro , PureTech,s ...
(Date:5/25/2015)... Where is the universe expanding to? Global ... answer is that nobody is entirely sure." , Uldrich ... month of June, starting with the ULI Florida Leadership ... top tech trends. And one of the most intriguing ... is expanding to. According to Einstein’s theory of general ...
(Date:5/25/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. Major companies ... Linde Industrial Gas, Basf, Air Products, Air Liquide, ... Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) Chemical, ...
Breaking Biology Technology:In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 2Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 3Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3
... ... a standard tool in the chemical and pharmaceutical industries for providing information ... development and scale-up of chemical processes. METTLER TOLEDO is offering a ... Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today reported financial results ... a net loss for the third quarter of 2009 of $9.4 ... Company,s expectations. This compares to a net loss for the third ... Research and development expenses in the third quarter of 2009 were ...
... WILMINGTON, Del., Nov. 3 Fertili-Plus(TM) today introduced the ... 5-step, definitive, and easy-to-follow guide, when trying ... a free e-book publication, the Fertili-Plus Conception Framework equips ... their fertility and reproductive health, and increase their chances ...
Cached Biology Technology:Development of Batch and Continuous Chemical Processes Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Fertili-Plus Introduces 5-Step Conception Framework 2
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... issue of the journal Botany is set ... researchers are bringing to the study of pollination biology. ... researchers, examining topics that range from the effect of ... recent climate change on pollinator ranges. The issue also ...
... Ohio Loss of a particular microRNA in chronic lymphocytic ... mechanisms that enable cancer cells to produce the energy and ... tissue. , The findings come from a new study led ... Arthur G. James Cancer Hospital and Richard J. Solove ...
... the University of Colorado Boulder indicates air pollution in ... automobiles and agriculture is changing the alpine vegetation in ... nitrogen compounds to the atmosphere are being carried to ... CU-Boulder Professor William Bowman, who directs CU-Boulder,s Mountain Research ...
Cached Biology News:Special issue of Botany showcases CANPOLIN research 2miR loss may power maligant transformation in chronic leukemia 2Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study 2Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study 3
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Biology Products: